Sodium butyrateHistone deacetylase inhibitor; directs differentiation of mESCs into hepatocytes CAS# 156-54-7 |
- Tiratricol
Catalog No.:BCC4738
CAS No.:51-24-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 156-54-7 | SDF | Download SDF |
PubChem ID | 5222465 | Appearance | Powder |
Formula | C4H7NaO2 | M.Wt | 110.09 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Butanoic acid sodium salt | ||
Solubility | H2O : 100 mg/mL (908.35 mM; Need ultrasonic) DMSO : 1 mg/mL (9.08 mM; Need ultrasonic) | ||
Chemical Name | sodium;butanoate | ||
SMILES | CCCC(=O)[O-].[Na+] | ||
Standard InChIKey | MFBOGIVSZKQAPD-UHFFFAOYSA-M | ||
Standard InChI | InChI=1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Histone deacetylase inhibitor. Restores contextual memory in a transgenic mouse model of Alzheimer's disease. Shown to induce pancreatic progenitor formation. Directs the differentiation of mouse embryonic stem cells into hepatocytes when used in combination with the cytokine Activin A. Also augments transcription factor stimulated iPSC generation. |
Sodium butyrate Dilution Calculator
Sodium butyrate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 9.0835 mL | 45.4174 mL | 90.8348 mL | 181.6695 mL | 227.0869 mL |
5 mM | 1.8167 mL | 9.0835 mL | 18.167 mL | 36.3339 mL | 45.4174 mL |
10 mM | 0.9083 mL | 4.5417 mL | 9.0835 mL | 18.167 mL | 22.7087 mL |
50 mM | 0.1817 mL | 0.9083 mL | 1.8167 mL | 3.6334 mL | 4.5417 mL |
100 mM | 0.0908 mL | 0.4542 mL | 0.9083 mL | 1.8167 mL | 2.2709 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Sodium butyrate
- 4-Hydroxyphenylacetic acid
Catalog No.:BCN4795
CAS No.:156-38-7
- Rabdoternin F
Catalog No.:BCN6399
CAS No.:155977-87-0
- Edultin
Catalog No.:BCC8321
CAS No.:15591-75-0
- Gipsoside
Catalog No.:BCN8482
CAS No.:15588-68-8
- LE 135
Catalog No.:BCC7242
CAS No.:155877-83-1
- 9,10-Dimethoxycanthin-6-one
Catalog No.:BCN3106
CAS No.:155861-51-1
- RJR-2403
Catalog No.:BCC1901
CAS No.:15585-43-0
- BW 373U86
Catalog No.:BCC5798
CAS No.:155836-50-3
- 5-O-Methylhierochin D
Catalog No.:BCN4526
CAS No.:155836-29-6
- 25-O-Methylalisol A
Catalog No.:BCN3456
CAS No.:155801-00-6
- 3-beta-O-(cis-p-Coumaroyl)corosolic acid
Catalog No.:BCN1553
CAS No.:155800-17-2
- 4-IBP
Catalog No.:BCC6777
CAS No.:155798-08-6
- H-HoArg-OH
Catalog No.:BCC3226
CAS No.:156-86-5
- Angelidiol
Catalog No.:BCN7964
CAS No.:156009-77-7
- Qianhucoumarin E
Catalog No.:BCN3506
CAS No.:156041-02-0
- Alvimopan
Catalog No.:BCC1347
CAS No.:156053-89-3
- SGC 0946
Catalog No.:BCC2216
CAS No.:1561178-17-3
- Lys-γ3-MSH
Catalog No.:BCC6049
CAS No.:156159-18-1
- BQ-788 sodium salt
Catalog No.:BCC5151
CAS No.:156161-89-6
- Maackiaflavanone
Catalog No.:BCN6834
CAS No.:156162-10-6
- CEP 1347
Catalog No.:BCC7982
CAS No.:156177-65-0
- Hispidulin 7-O-neohesperidoside
Catalog No.:BCN2952
CAS No.:156186-00-4
- GTS 21 dihydrochloride
Catalog No.:BCC7948
CAS No.:156223-05-1
- PyAOP
Catalog No.:BCC2819
CAS No.:156311-83-0
Inhibition of store-operated Ca(2+) entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate.[Pubmed:28356979]
Oncol Lett. 2017 Feb;13(2):921-929.
Sodium butyrate (NaBu), a histone deacetylase inhibitor, has demonstrated anti-tumor effects in several cancers, and is a promising candidate chemotherapeutic agent. However, its roles in nasopharyngeal carcinoma (NPC), an endemic malignant disease in Southern China and Southeast Asia, has rarely been studied. In the present study, MTT assay, colony formation assay, flow cytometry analysis and western blotting were performed to explore the influence of NaBu on NPC cells and its underlying mechanism. NaBu induced morphological changes and inhibited proliferation in 5-8F and 6-10B cells. MTT assay revealed that NaBu was cytotoxic to 5-8F and 6-10B cells in a dose- and time-dependent manner. Furthermore, flow cytometry analysis revealed that NaBu induced obvious cell apoptosis in 5-8F and 6-10B cells due to the activation of the mitochondrial apoptosis axis. In addition, flow cytometry analysis and western blotting demonstrated that NaBu could enhance the Ca(2+) influx by promoting store-operated Ca(2+) entry (SOCE) in 5-8F and 6-10B cells. Inhibition of SOCE by specific inhibitors or downregulated expression of calcium release-activated calcium channel protein 1 and stromal interaction molecule 1 could counteract the apoptosis of NPC cells induced by NaBu. Thus, the current study revealed that enhanced SOCE and activated mitochondrial apoptosis axis may account for the mechanisms of cytotoxicity of NaBu in NPC cells, and that NaBu serves as a promising chemotherapeutic agent in NPC therapy.
Label-free protein quantification of sodium butyrate treated CHO cells by ESI-UHR-TOF-MS.[Pubmed:28363874]
J Biotechnol. 2017 Sep 10;257:87-98.
Effects of butyrate on CHO producer cells are contradictory, promoting productivity and at the same time repressing proliferation. Though in previous omics studies the background of butyrate impact on producer cells has been investigated, the knowledge about the mechanism is still very limited. As previous proteomic results on this field are mainly based on 2DE-gels, we conducted a label-free MS quantification, based on fast high resolution ESI-MS and a straight forward software solution, to gain insight in shifted cellular processes of CHO cells 25h after butyrate treatment. 118 proteins or subunits with significantly altered abundances were identified suggesting changes in carbohydrate, protein metabolic and cell cycle processes. Effects of butyrate on the nucleosome assembly as a known direct epigenetic influence on HDAC activity turned out to be unexpectedly fast and persistent, as confirmed by Western blots of histone-H4 acetylation. Contradictory to increased cell specific productivity, most elements of protein metabolism exhibited decreased levels after butyrate treatment. In comparison to published results some overlap of our label free MS data could be observed but also apparently diverging findings, showing the need for complementary omics techniques for a holistic view on cellular processes such as response to butyrate.
Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage.[Pubmed:28369321]
Hum Mol Genet. 2017 Jun 15;26(12):2231-2246.
Alpha-synuclein (aSyn) is considered a major culprit in Parkinson's disease (PD) pathophysiology. However, the precise molecular function of the protein remains elusive. Recent evidence suggests that aSyn may play a role on transcription regulation, possibly by modulating the acetylation status of histones. Our study aimed at evaluating the impact of wild-type (WT) and mutant A30P aSyn on gene expression, in a dopaminergic neuronal cell model, and decipher potential mechanisms underlying aSyn-mediated transcriptional deregulation. We performed gene expression analysis using RNA-sequencing in Lund Human Mesencephalic (LUHMES) cells expressing endogenous (control) or increased levels of WT or A30P aSyn. Compared to control cells, cells expressing both aSyn variants exhibited robust changes in the expression of several genes, including downregulation of major genes involved in DNA repair. WT aSyn, unlike A30P aSyn, promoted DNA damage and increased levels of phosphorylated p53. In dopaminergic neuronal cells, increased aSyn expression led to reduced levels of acetylated histone 3. Importantly, treatment with Sodium butyrate, a histone deacetylase inhibitor (HDACi), rescued WT aSyn-induced DNA damage, possibly via upregulation of genes involved in DNA repair. Overall, our findings provide novel and compelling insight into the mechanisms associated with aSyn neurotoxicity in dopaminergic cells, which could be ameliorated with an HDACi. Future studies will be crucial to further validate these findings and to define novel possible targets for intervention in PD.
Effects of ultra-high dilutions of sodium butyrate on viability and gene expression in HEK 293 cells.[Pubmed:28325222]
Homeopathy. 2017 Feb;106(1):32-36.
BACKGROUND: Several recent studies reported the capability of high diluted homeopathic medicines to modulate gene expression in cell cultures. In line with these studies, we examined whether ultra-high dilutions (30C and 200C) of Sodium butyrate (SB) can affect the expression levels of genes involved in acquisition of a senescence-associated secretory phenotype (SASP) in human embryonic kidney (HEK) 293 cells. METHODS: Cell viability was evaluated using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. The expression levels of TNF-alpha, interleukin (IL)-2, IL-4, IL-6 and IL-10 genes were determined by real-time PCR assay. RESULTS: Exposure to both 30C and 200C during 48 h led to a significant decrease of the level of expression of TNF-alpha gene, while expression of IL-2 gene was increased when exposed to 30C, and expression of IL-10 gene was decreased when exposed to 200C. No changes in expression levels of all genes studied were observed in cells treated with both 30C and 200C remedies of SB during the 24 h. CONCLUSION: Observed changes in gene expression levels after exposure to 30C and 200C remedies of SB during 48 h suggest that extremely low concentrations of this agent can modulate the transcriptome of HEK 293 cells. These results are in line with findings from other studies confirming the ability of homeopathic remedies to modulate gene expression in cell cultures.
Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease.[Pubmed:20010553]
Neuropsychopharmacology. 2010 Mar;35(4):870-80.
Alzheimer's disease (AD) is a neurodegenerative disorder characterized clinically by cognitive impairments that progress to dementia and death. The earliest symptoms of AD present as a relatively pure deficit in memory retrieval. Therefore, drug treatments that intervene in the early stages of AD by rescuing memory deficits could be promising therapies to slow, or even reverse progression of the disease. In this study, we tested the potential of systemic histone deacetylase inhibitor (HDACi) treatment to rescue cognitive deficits in a mouse model of AD. APPswe/PS1dE9 mice showed pronounced contextual memory impairments beginning at 6 months of age. Chronic HDACi injections (2-3 weeks) did not alter contextual memory formation in normal mice, but had profound effects in transgenic animals. Injections of sodium valproate, Sodium butyrate, or vorinostat (suberoylanilide hydroxamic acid; Zolinza) completely restored contextual memory in these mutant mice. Further behavioral testing of the HDACi-treated transgenic mice showed that the newly consolidated memories were stably maintained over a 2-week period. Measurement of the HDAC isoform selectivity profile of sodium valproate, Sodium butyrate, and vorinostat revealed the common inhibition of class I HDACs (HDAC1, 2, 3, 8) with little effect on the class IIa HDAC family members (HDAC4, 5, 7, 9) and inhibition of HDAC6 only by vorinostat. These preclinical results indicate that targeted inhibition of class I HDAC isoforms is a promising avenue for treating the cognitive deficits associated with early stage AD.
Butyrate promotes induced pluripotent stem cell generation.[Pubmed:20554530]
J Biol Chem. 2010 Aug 13;285(33):25516-21.
Recent studies have demonstrated that embryonic stem cell-like induced pluripotent stem (iPS) cells can be generated by enforced expression of defined transcription factors. The fact that cell fate change is accompanied by changes in epigenetic modifications prompted us to investigate whether chemicals known to modulate epigenetic regulators are capable of enhancing the efficiency of iPS cell generation. Here, we report that butyrate, a natural small fatty acid and histone deacetylase inhibitor, significantly increases the efficiency of mouse iPS cell generation using the transcription factors Oct4, Sox2, Klf4, and c-Myc. We show that butyrate not only changes the reprogramming dynamics, but also increases the ratio of iPS cell colonies to total colonies by reducing the frequency of partially reprogrammed cells and transformed cells. Detailed analysis reveals that the effect of butyrate on reprogramming appears to be mediated by c-Myc and occurs during an early stage of reprogramming. Genome-wide gene expression analysis reveals up-regulation of ES cell-enriched genes when mouse embryonic fibroblasts are treated with butyrate during reprogramming. Thus, our study identifies butyrate as a chemical factor capable of promoting iPS cell generation.
Effects of sodium butyrate on the differentiation of pancreatic and hepatic progenitor cells from mouse embryonic stem cells.[Pubmed:19911386]
J Cell Biochem. 2010 Jan 1;109(1):236-44.
Recently significant progress has been made in differentiating embryonic stem (ES) cells toward pancreatic cells. However, little is known about the generation and identification of pancreatic progenitor cells from ES cells. Here we explored the influence of Sodium butyrate on pancreatic progenitor differentiation, and investigated the different effects of Sodium butyrate on pancreatic and hepatic progenitor formation. Our results indicated that different concentration and exposure time of Sodium butyrate led to different differentiating trends of ES cells. A relatively lower concentration of Sodium butyrate with shorter exposure time induced more pancreatic progenitor cell formation. When stimulated by a higher concentration and longer exposure time of Sodium butyrate, ES cells differentiated toward hepatic progenitor cells rather than pancreatic progenitor cells. These progenitor cells could further mature into pancreatic and hepatic cells with the supplement of exogenous inducing factors. The resulting pancreatic cells expressed specific markers such as insulin and C-peptide, and were capable of insulin secretion in response to glucose stimulation. The differentiated hepatocytes were characterized by the expression of a number of liver-associated genes and proteins, and had the capability of glycogen storage. Thus, the current study demonstrated that Sodium butyrate played different roles in inducing ES cells toward pancreatic or hepatic progenitor cells. These progenitor cells could be further induced into mature pancreatic cells and hepatocytes. This finding may facilitate the understanding of pancreatic and hepatic cell differentiation from ES cells, and provide a potential source of transplantable cells for cell-replacement therapies.
Differentiation of mouse embryonic stem cells into hepatocytes induced by a combination of cytokines and sodium butyrate.[Pubmed:20039312]
J Cell Biochem. 2010 Feb 15;109(3):606-14.
There is increasing evidence to suggest that embryonic stem cells (ESCs) are capable of differentiating into hepatocytes in vitro. In this study, we used a combination of cytokines and Sodium butyrate in a novel three-step procedure to efficiently direct the differentiation of mouse ESCs into hepatocytes. Mouse ESCs were first differentiated into definitive endoderm cells by 3 days of treatment with Activin A. The definitive endoderm cells were then differentiated into hepatocytes by the addition of acidic fibroblast growth factor (aFGF) and Sodium butyrate to the culture medium for 5 days. After 10 days of further in vitro maturation, the morphological and phenotypic markers of hepatocytes were characterized using immunohistochemistry, immunoblotting, and reverse transcription-polymerase chain reaction (RT-PCR). Furthermore, the cells were tested for functions associated with mature hepatocytes, including glycogen storage and indocyanine green uptake and release, and the ratio of hepatic differentiation was determined by counting the percentage of albumin-positive cells. In the presence of medium containing cytokines and Sodium butyrate, numerous epithelial cells resembling hepatocytes were observed, and approximately 74% of the cells expressed the hepatic marker, albumin, after 18 days in culture. RT-PCR analysis and immunohistochemistry showed that these cells expressed adult liver cell markers, and had the abilities of glycogen storage and indocyanine green uptake and release. We have developed an efficient method for directing the differentiation of mouse ESCs into cells that exhibit the characteristics of mature hepatocytes. This technique will be useful for research into the molecular mechanisms underlying liver development, and could provide a source of hepatocytes for transplantation therapy and drug screening.
Suppression of histone deacetylation in vivo and in vitro by sodium butyrate.[Pubmed:649576]
J Biol Chem. 1978 May 25;253(10):3364-6.
In HeLa cells which have been exposed to 5 mM Sodium butyrate for 21 h, the level of histone acetylation is greatly increased as compared to control cells (Riggs, M.G., Whittaker, R.G., Neumann, J.R., and Ingram, V.R. (1977) Nature 268, 462-464). Our experiments indicate that the increase in the relative amounts of multiacetylated forms of histones H4 and H3 following butyrate treatment is the result of an inhibition of histone deacetylase activity.